Sa1203 Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Honghui Zhou(Janssen (United States)), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Hugh M. Davis(South College), Zhenhua Xu(Beijing Institute of Education), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University), Joyce Ford
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k